<DOC>
	<DOCNO>NCT00984035</DOCNO>
	<brief_summary>The purpose study identify novel biomarkers kidney injury patient receive cisplatin . This study also collect DNA future analysis .</brief_summary>
	<brief_title>Investigation Cisplatin-Related Kidney Toxicity</brief_title>
	<detailed_description>This study look novel biomarkers kidney injury patient receive cisplatin patient currently receive cisplatin . DNA collect prospectively retrospectively ( patient previously receive cisplatin .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Prospective Analysis Group Patients receive intravenous cisplatin first time part cancer chemotherapy . Aged 18 year old . Ability understand willingness sign write consent document . Patients may receive cisplatin combination chemotherapeutic agent . Patients may receive cisplatin context another clinical trial . Prior receipt cisplatin . Patients dialysis renal replacement therapy prior start cisplatin . Uncontrolled hypo hyperthyroidism ( patient chronic stable dos thyroid replacement medication eligible ) . Retrospective Analysis Group Patients previously receive intravenous cisplatin part cancer chemotherapy . Aged 18 year old . Ability understand willingness sign write consent document . Patients receive cisplatin combination chemotherapeutic agent eligible . Patients receive cisplatin context clinical trial eligible . Unable unwilling submit onetime blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>